The most promising diquinothiazine, 6-chloro-ethylureidoethyldiquinothiazine, exerted suppressive and anti-inflammatory activities in the above-mentioned in vivo models, and showed inhibitory activity of IFNβ expression and IFNβ-dependent downstream genes and proteins involved in the pathogenesis of autoimmune diseases [28,29,30,31,32]. Here, IFNB1 is linked to autoimmune disease.